Cost-effectiveness Analysis of Pembrolizumab in Combination with Chemotherapy Compared with Chemotherapy Alone As First-line Treatment for Patients with Advanced Biliary Tract Cancer in China

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Sep 4

PMID 37667230

Authors

Zhiwei Zheng

Ling Fang

Hongfu Cai

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study is to evaluate the cost-effectiveness of adding pembrolizumab to the standard first-line therapy of advanced biliary tract cancer (BTC) with gemcitabine and cisplatin from the perspective of the Chinese healthcare system.

Methods: The partitioned survival model developed from clinical data obtained in The KEYNOTE-966 trial served as the basis for a simulation in the TreeAge Pro 2011 software. The objective of the research was to estimate the 10-year life expectancy and total healthcare costs of patients with BTC, utilizing primary outcomes that evaluated costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). To establish the willingness-to-pay (WTP) threshold, the 2022 Chinese per capita gross domestic product (GDP) of $37304.346/QALY was adopted. Furthermore, sensitivity analysis was conducted to ascertain the study's results under varying levels of uncertainty.

Results: Compared to chemotherapy alone, the addition of pembrolizumab to chemotherapy has been shown to yield an incremental gain of 0.184 quality-adjusted life years (QALY) at an additional cost of $103940.706. This translates into an incremental cost-effectiveness ratio (ICER) of $564895.141/QALY, which exceeds the willingness-to-pay (WTP) threshold in China. One-way sensitivity analyses performed on the model recognize the utility of PD, subsequent cost, and the cost of Pembrolizumab 100 mg had a major influence on the outcomes. However, no parameter elicited an ICER lower than the willingness-to-pay (WTP) threshold.

Conclusions: Based on the perspective of the Chinese healthcare system, the utilization of pembrolizumab in combination with chemotherapy as an first-line treatment option for BTC does not appear to be a cost-effective approach compared to chemotherapy as a standalone therapy.

Citing Articles

Cost-effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer.

Liu R, Zhao Y, Shi F, Zhu J, Wu J, Huang M Immunotherapy. 2024; 16(10):669-678.

PMID: 39259510 PMC: 11404697. DOI: 10.1080/1750743X.2024.2347822.

Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer.

Kashiwa M, Maeda H J Gastrointest Cancer. 2024; 55(4):1569-1580.

PMID: 39172318 DOI: 10.1007/s12029-024-01106-7.

Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis.

Mauro E, Sanduzzi-Zamparelli M, Sauri T, Soler A, Iserte G, Fortuny M Cancers (Basel). 2024; 16(11).

PMID: 38893196 PMC: 11171222. DOI: 10.3390/cancers16112077.

Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool.

Ma Y, Pan Y, Li Y, Guan H, Dai G J Cancer Res Clin Oncol. 2024; 150(5):247.

PMID: 38722378 PMC: 11081983. DOI: 10.1007/s00432-024-05771-w.

References

Kam A, Masood A, Shroff R . Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol. 2021; 6(11):956-969. DOI: 10.1016/S2468-1253(21)00171-0. View

Neuzillet C, Artru P, Assenat E, Edeline J, Adhoute X, Sabourin J . Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Target Oncol. 2023; 18(1):51-76. PMC: 9928940. DOI: 10.1007/s11523-022-00942-6. View

Valle J, Kelley R, Nervi B, Oh D, Zhu A . Biliary tract cancer. Lancet. 2021; 397(10272):428-444. DOI: 10.1016/S0140-6736(21)00153-7. View

Wang Y, Wen N, Wang S, Nie G, Tian Y, Lu J . Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review. BMC Cancer. 2023; 23(1):378. PMC: 10131316. DOI: 10.1186/s12885-023-10679-8. View

Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L . The state of therapy modalities in clinic for biliary tract cancer. Front Biosci (Landmark Ed). 2022; 27(6):185. DOI: 10.31083/j.fbl2706185. View

Vogel A, Bridgewater J, Edeline J, Kelley R, Klumpen H, Malka D . Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(2):127-140. DOI: 10.1016/j.annonc.2022.10.506. View

LaPelusa M, Heumann T, Goff L, Agarwal R . Targeted therapies in advanced biliary tract cancers-a narrative review. Chin Clin Oncol. 2023; 12(2):14. PMC: 10175163. DOI: 10.21037/cco-22-93. View

Queiroz M, Lima Jr N, de Castria T . Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza. Cancers (Basel). 2023; 15(7). PMC: 10093144. DOI: 10.3390/cancers15071970. View

Oh D, Lee K, Lee D, Yoon J, Kim T, Bang J . Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022; 7(6):522-532. DOI: 10.1016/S2468-1253(22)00043-7. View

10.

Sun J, Shen L, Shah M, Enzinger P, Adenis A, Doi T . Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021; 398(10302):759-771. DOI: 10.1016/S0140-6736(21)01234-4. View

11.

Ren S, Feng J, Ma S, Chen H, Ma Z, Huang C . KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. Int J Cancer. 2023; 153(3):623-634. DOI: 10.1002/ijc.34532. View

12.

Kelley R, Ueno M, Yoo C, Finn R, Furuse J, Ren Z . Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10391):1853-1865. DOI: 10.1016/S0140-6736(23)00727-4. View

13.

Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M . Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2020; 28(1):26-54. DOI: 10.1002/jhbp.870. View

14.

Borakati A, Froghi F, Bhogal R, Mavroeidis V . Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances. World J Gastroenterol. 2023; 29(13):1969-1981. PMC: 10122785. DOI: 10.3748/wjg.v29.i13.1969. View

15.

Guyot P, Ades A, Ouwens M, Welton N . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. PMC: 3313891. DOI: 10.1186/1471-2288-12-9. View

16.

Hoyle M, Henley W . Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011; 11:139. PMC: 3198983. DOI: 10.1186/1471-2288-11-139. View

17.

Diaby V, Adunlin G, Montero A . Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2013; 32(2):101-8. DOI: 10.1007/s40273-013-0123-9. View

18.

Ye Z, Xu Z, Li H, Li Q . Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer. Front Public Health. 2023; 11:1046424. PMC: 9950513. DOI: 10.3389/fpubh.2023.1046424. View

19.

Zhao Q, Xie R, Zhong W, Liu W, Chen T, Qiu X . Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Cost Eff Resour Alloc. 2023; 21(1):19. PMC: 9979442. DOI: 10.1186/s12962-023-00429-9. View

20.

Zheng Z, Zhu H, Fang L, Cai H . Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer. Front Pharmacol. 2022; 13:996914. PMC: 9511109. DOI: 10.3389/fphar.2022.996914. View